We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Biologics contract manufacturer Omnia Biologics, Inc. (Rockville, Md.) and biopharmaceutical
technology development company, AT-GC BioPharm, Inc. (Baltimore, Md.) announced
the signing of a strategic alliance to develop AT-GC Electronic Eye technology
for the manufacture of biopharmaceutical products.
The Chennai-based pharma major, Orchid Chemicals & Pharmaceuticals Ltd (Orchid),
has entered into an exclusive agreement with STADA Pharmaceuticals Inc, the
U.S. subsidiary of STADA Arzneimittel AG, for the development and supply of
six prescription generic drug products to STADA for the US market.
GlaxoSmithKline Plc said on Thursday its asthma drug Advair/Seretide beat AstraZeneca
Plc's Symbicort in a one-year clinical study, reviving rival claims about the
two products.
Biotechnology company Icoria, announced that it is transitioning from agricultural
R&D activities to concentrate on an aggressive program to discover and validate
targets and potential drug candidates for the treatment of diabetes, obesity
and liver injury.
Savient Pharmaceuticals, Inc. has signed a definitive agreement with Ferring
Pharmaceuticals, a subsidiary of Ferring B.V., to enter a co-promotion agreement
to market Nuflexxa (1 percent Sodium Hyaluronate) in the United States.
Celgene announced that it has signed a licensing
agreement with EntreMed Corporation whereby EntreMed has been granted rights
to the development and commercialization of Celgene's tubulin inhibitor compounds,
a class of orally available, anti-proliferative compounds that have demonstrated,
in preclinical models, activity against drug-resistant cancer cells, inhibition
of inflammatory cytokines and anti-angiogenic activity.
Eli Lilly's Xigris may increase the risk of death in sepsis patients with single-organ
dysfunction who recently underwent surgery, the FDA warned in a MedWatch alert.
The FDA is nearing approval of a proposal that will grant OTC status to Barr
Pharmaceuticals' emergency contraceptive Plan B, according to the agency's acting
Commissioner Lester Crawford.
A proposal to grant the HHS secretary the authority
to negotiate Medicare drug prices with manufacturers has been defeated in the
Senate by a single vote.
The FDA has issued a nationwide alert to healthcare facilities warning against
using a certain lot of magnesium sulfate solution, which the agency said may
contain harmful bacteria.